SUBSCRIBE
SUBSCRIBE

Postmarket research

Drug Development
BioPharm Executive: From the Bench to the Clinic
Alnylam’s victory with Patisiran in familial amyloid polyneuropathy (FAP) is significant for more than just the company and its patients.
October 14, 2017
 · 
1 min read
 · 
Karl Thiel
Drug Development
Johnson & Johnson’s New Xarelto Data Could Bring In $1.5 Billion In The U.S. Alone
August 28, 2017
 · 
1 min read
Why This Tiny Biotech is Giving Cash to Amgen Researchers
Drug Development
UCSF Heart Doctor Wary of Amgen-Paid Repatha Study
March 22, 2017
 · 
3 min read
Why This Tiny Biotech is Giving Cash to Amgen Researchers
Drug Development
Disappointment Hits as Amgen’s Repatha Prevents Heart Attacks, But Not Deaths
March 17, 2017
 · 
4 min read
Drug Development
Investors Anxiously Await for Amgen’s 27,500-Patient Heart Trial Data This Week
March 13, 2017
 · 
1 min read
Pharma Giant AstraZeneca PLC Scores Another FDA Breakthrough
Drug Development
AstraZeneca PLC Suffers Another Blow After Blood-Thinning Drug Flunks Trial
October 4, 2016
 · 
2 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Drug Development
Novo Nordisk A/S Investors Disappointed as Top Selling Drug Victoza Didn’t Do as Well as Expected
June 14, 2016
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Gilead Shuts Down Six Zydelig Trials Following European Medicines Agency Review
March 16, 2016
 · 
3 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Valeant Accused of Hiding Cold Drug Study Results Proving Drug Was No More Effective than a Placebo
February 2, 2016
 · 
3 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Regeneron Investors Get Jitters From False Praluent Data
January 7, 2016
 · 
2 min read
Load More
PRESS RELEASES
News
Tenon(R) Medical Announces First Peer Reviewed Publication of the MAINSAIL(TM) Study Analyzing the First 33 Consecutive Patients from an IRB Approved, Prospective, Multi-Centered, Post-Market Clinical Investigation Utilizing the Catamaran(R) SI Joint Fusion System
September 6, 2024
 · 
8 min read
Drug Development
Corcept Completes Enrollment in Phase 4 CATALYST Trial
April 29, 2024
 · 
3 min read
Business
Parexel and Palantir Expand Collaboration to Accelerate Clinical Data Delivery and Power Clinical Outcomes for Patients
April 25, 2024
 · 
6 min read
Drug Development
Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets
April 16, 2024
 · 
11 min read
Drug Development
Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
January 5, 2024
 · 
10 min read
Drug Development
Dermavant Announces Positive Results from Phase 4 Open-Label Trial of VTAMA® (tapinarof) Cream, 1% for the Treatment of Plaque Psoriasis in the Head and Neck Region in Adults
December 6, 2023
 · 
10 min read
Drug Development
AMGEN PRESENTS NEW RESEARCH IN EARLY PSORIATIC ARTHRITIS AT ACR 2023
November 7, 2023
 · 
17 min read
Drug Development
MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 Diabetes
November 6, 2023
 · 
3 min read
Drug Development
Dermavant Presents Positive Results from Phase 4 Open-Label Trial of VTAMA® (tapinarof) Cream, 1% for the Treatment of Intertriginous Plaque Psoriasis in Adults at 43rd Annual Fall Clinical Dermatology Conference
October 20, 2023
 · 
10 min read
Drug Development
Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder
October 17, 2023
 · 
8 min read
Drug Development
CEQUA® (cyclosporine ophthalmic solution) 0.09% Phase 4 Data Showed Sustained Improvement in Dry Eye Disease Signs and Symptoms in Patients Switched From Restasis® (cyclosporine ophthalmic emulsion) 0.05%
October 12, 2023
 · 
10 min read
Drug Development
First-Ever Clinical Trial Exclusively in Black and Hispanic / Latinx People Living With Multiple Sclerosis Shows Genentech’s Ocrevus Effectively Manages Disease Activity
October 11, 2023
 · 
15 min read
Drug Development
CymaBay Initiates AFFIRM, a Phase 3b/4 Study Evaluating the Effect of Seladelpar on Clinical Outcomes in Patients with Cirrhosis due to Primary Biliary Cholangitis
September 21, 2023
 · 
5 min read
Business
Samsung Bioepis & Organon Announce Topline Results from Interchangeability Study of SB5 Humira Biosimilar
August 1, 2023
 · 
15 min read
Drug Development
SKYRIZI® (risankizumab) Achieved Superiority Versus Apremilast for Co-Primary Endpoints Among Adult Patients with Moderate Plaque Psoriasis in Phase 4 Head-to-Head Study
July 26, 2023
 · 
12 min read
Drug Development
Grifols Achieves Positive Topline Results From Phase 4 Study of XEMBIFY® (immune globulin subcutaneous human-klhw) Evaluating Biweekly Dosing Option for Patients
July 20, 2023
 · 
10 min read
Drug Development
Akebia Therapeutics Announces Positive Top-Line Results of Phase 4 IMPACT Study of Auryxia® (ferric citrate) for In-Center and Home Dialysis Patients
June 29, 2023
 · 
7 min read
Drug Development
Additional Data from Phase 4 TEPEZZA® (teprotumumab-trbw) Clinical Trial Presented at the Endocrine Society Annual Meeting Reinforces Efficacy in People with Thyroid Eye Disease (TED) Regardless of Disease Activity or Duration
June 17, 2023
 · 
9 min read
Drug Development
ANDEXXA Phase IV Trial Stopped Early After Achieving Pre-specified Criteria on Hemostatic Efficacy Versus Usual Care
June 5, 2023
 · 
13 min read
Drug Development
Horizon Therapeutics plc Announces Positive Topline Data from TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
April 10, 2023
 · 
9 min read
Load More